Understand the source comparison
Best Peptides for Gastritis: Comprehensive Comparison
The following table compares the three peptides with the strongest published evidence for gastric mucosal repair, along with their mechanisms, typical research dosing, and relevant clinical considerations. BPC-157 (Body Protection Compound-157) VEGF-mediated a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares the three peptides with the strongest published evidence for gastric mucosal repair, along with their mechanisms, typical research dosing, and relevant clinical considerations.
- BPC-157 (Body Protection Compound-157)
- VEGF-mediated angiogenesis, fibroblast growth factor upregulation, nitric oxide pathway modulation
- 10 mcg/kg subcutaneously or intraperitoneally daily
- University of Zagreb studies: 60% faster ulcer closure vs controls at 14 days; histological evidence of collagen deposition and re-epithelialization
- Strongest preclinical evidence for direct gastric ulcer healing; requires peptide sequence integrity and precise dosing
- KPV (Lys-Pro-Val Tripeptide)
- NF-kB inhibition, TNF-alpha and IL-6 suppression, reduced inflammatory cytokine transcription
- 5–20mg daily oral or sublingual
- University of Arizona colitis models: reduced mucosal inflammation scores, preserved epithelial barrier function
- Anti-inflammatory mechanism complements mucosal repair; oral bioavailability documented in IBD models
- Thymosin Beta-4
- Actin sequestration, epithelial cell migration, extracellular matrix remodeling, G-actin binding
- 1.5–6mg weekly subcutaneously
- Gastroenterology study: 45% reduction in gastric ulcer area via enhanced epithelial restitution in ethanol-induced models
- Critical for ulcer closure through cell motility; synergistic with angiogenic peptides